Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Satellite Symposia webcasts

ESMO-Congress-2022-1000x1000

Watch the webcasts from our industry partners' Satellite Symposia

09/09/2022

Janssen-Cilag International NV
Catching it early, getting it right: optimal disease and patient management from biomarkers to treatment selection

Watch session

  • Welcome and Introduction
    Maria De Santis
  • Patient case presentation and discussion: From the pathologist's and urologists' perspectives
    Maria De Santis, Thomas B. Powles, Eva Comperat, Shahrokh F. Shariat
  • Patient case analysis: how do we select the best treatment in challenging cases?
    Maria De Santis, Thomas B. Powles, Eva Comperat, Shahrokh F. Shariat
  • Treatment selection and managing patients safety: a discussion on the treatment landscape
    Maria De Santis, Thomas B. Powles, Eva Comperat, Shahrokh F. Shariat
  • Audience Q&A
    Maria De Santis, Thomas B. Powles, Eva Comperat, Shahrokh F. Shariat
  • Summary and close
    Thomas Powles

Bristol Myers Squibb
GI Cancer and Immuno-Oncology Today: Best Practice and Clinical Challenges

Watch session

  • Welcome and Introduction
    Myriam Chalabi
  • Current Status of I-O for Treating CRC
    Myriam Chalabi
  • Treating Gastric Cancer Today: I-O-focused Update
    Kei Muro
  • Emerging Treatments for Esophageal Cancer:  First-Line Metastatic Disease and Earlier Stages
    Emmanuelle Samalin-Scalzi
  • Roundtable Case Discussion, Q&A, and Summary
    Ian Chau
  • Close
    Ian Chau

F. Hoffmann-La Roche Ltd
Navigating the possibilities of personalised healthcare in oncology

Watch session

  • A guide to the expanding possibilities in personalised healthcare
    Allan Hackshaw
  • Cancer of unknown primary: Making the unknown known
    Alwin Krämer
  • Panel discussion: Progress in personalised healthcare
    Allan Hackshaw, Alwin Krämer, Jean-Yves Blay, Charles Alessi, Warnyta Minnaard
  • Staying at the frontier of comprehensive genomic profiling and liquid biopsy
    Jean-Yves Blay
  • The value of real-world data for augmenting personalised healthcare at several levels
    Allan Hackshaw
  • Panel discussion: Putting the possibilities into practice
    Allan Hackshaw, Jean-Yves Blay, Alwin Krämer, Charles Alessi, Warnyta Minnaard
  • Conclusion
    Allan Hackshaw

PeerView Oncology
Targeting HER2-Low Expression in Breast Cancer: Evaluating the Evidence, Challenges, and Opportunities for Expanding Treatment Benefit to More Patients

Watch session

  • Welcome and Introduction
    Aleix Prat
  • Understanding the Foundational Concepts of HER2-Low Breast Cancer: Challenges and Opportunities of an Evolving Definition
    Paolo Tarantino
  • Extending Anti-HER2 Therapy Benefits to a Larger Population of Patients: Emerging Evidence, Implementation in Clinical Practice, and Future Directions
    Shanu Modi
  • Unveiling the Biology of HER2-Low Breast Cancer: Insights From Genomics, Transcriptomics, and Opportunities With Evolving Testing Approaches
    Aleix Prat
  • Exploring the Nuances of HER2-Targeted Treatment Selection for Patients With HER2-Low Breast Cancer: Expert Insights Into Implications for Practice and Team-Based Approaches to Individualizing Patient Care
    Aleix Prat
  • Summary, Reflections, and Key Takeaways
    Aleix Prat

Servier
Interpreting real-world data to better manage patients with metastatic colorectal cancer

Watch session

  • Introduction
    Julien Taieb
  • Is there a need for real-world data?
    Chiara Cremolini
  • Real-world data in mCRC
    Miriam Koopman
  • Patient insights and perspectives on real-world data
    Francisca E. Marti
  • Optimization and management of treatment in mCRC
    Dominik P. Modest
  • Conclusion and Q&A
    Julien Taieb

10/09/2022

GSK
Avant-garde: Reframing the art of first-line maintenance therapy to optimise long-term outcomes in advanced ovarian cancer

Watch session

  • Welcome and introduction
    Gilles Freyer
  • State of the art: What are the most current data and updates to treatment guidelines for first-line maintenance in ovarian cancer
    Domenica Lorusso
  • The art of treatment selection: Importance and impact of early treatment planning
    Charlie Gourley
  • Articles of individualised treatment: How can we begin to individualise treatment using biomarkers and available therapies
    Gilles Freyer
  • Closing remarks
    Gilles Freyer

Boehringer Ingelheim International GmbH
Breaking Through the Firewall: New Therapeutic Strategies to Disrupt Cancer’s Operating Systems

Watch session

  • Welcome and Introductions
    Martin Reck
  • Development of an MDM2-p53 Antagonist for STS and Other Indications
    Patrick Schoeffski
  • Targeting HER2 and KRAS to Deliver Breakthrough Therapies
    Egbert F. Smit
  • T-cell Engagers: Change of the Treatment Paradigm in Solid Tumors
    Martin Reck
  • Expert Panel Q&A
    Martin Reck, Patrick Schoeffski, Egbert F. Smit
  • Closing Remarks
    Martin Reck

PeerVoice
Contemporary Management of Prostate Cancer: Updated Approaches for Improved Outcomes in nmCRPC and mHSPC

Watch session

  • Welcome, Faculty Introductions, and Overview of Agenda
    Karim Fizazi
  • State-of-the-Art Interventions in mHSPC: New Evidence, New Expectations
    Karim Fizazi, Alicia K. Morgans, Bertrand Tombal
  • Modernising the Standard of Care in nmCRPC: What Are We Waiting For?
    Karim Fizazi, Alicia K. Morgans, Bertrand Tombal
  • Key Questions and Expert Discussion With Programme Faculty
    Karim Fizazi, Alicia K. Morgans, Bertrand Tombal
  • Final Remarks, Conclusions, and Closing
    Karim Fizazi

Janssen-Cilag International NV
Exploring questions in metastatic prostate cancer 

Watch session

  • Welcome and introduction
    Laura-Maria Krabbe
  • Question 1: How should we manage oligometastatic disease?
    Joe O'Sullivan
  • Question 2: What is the role of chemotherapy alongside hormonal treatments in mHSPC?
    Gerhardt Attard, Laura-Maria Krabbe
  • Question 3: How do we choose treatment options for patients with mCRPC?
    Eleni Efstathiou
  • Close
    Gerhardt Attard

Janssen-Cilag International NV
Precision approaches in EGFR-mutant NSCLC: Optimising outcomes for patients

Watch session

  • Welcome & Introduction
    David Planchard
  • Updates in precision approaches to the molecular diagnosis of NSCLC
    Paul Hofman
  • Discussion: How can we address diagnostic challenges of NSCLC in clinical practice?
    David Planchard, Maria Rosario Garcia Campelo, Sanjay Popat, Anne-Marie C. Dingemans, Paul Hofman
  • New and emerging therapies for EGFR-mutant NSCLC
    Anne-Marie C. Dingemans
  • Discussion: What does the future hold for the management of EGFR-mutant NSCLC?
    David Planchard, Maria Rosario Garcia Campelo, Sanjay Popat, Anne-Marie C. Dingemans, Paul Hofman
  • Emerging treatment options for EGFR exon 20 insertions
    Sanjay Popat
  • Q&A
    David Planchard, Maria Rosario Garcia Campelo, Sanjay Popat, Anne-Marie C. Dingemans, Paul Hofman
  • Key learnings and closing remarks
    Maria Rosario Garcia Campelo

BeiGene Switzerland GmbH
Standard of Care is Not Enough! Talking Immunotherapy Clinical Trials in GI Cancers

Watch session

  • Welcome to the Conversation
    Lesley J. Fallowfield
  • What Now Doc? A Patient’s Perspective
    Tihana Gašpert
  • GI Cancers: Checkpoint Inhibitors and Beyond
    Elizabeth Smyth
  • Talking With Patients About Clinical Trials: How, What, Why, When and Where?
    Lesley J. Fallowfield
  • Questions about Trials? Connect With your Expert!
    Elizabeth Smyth, Eric Van Cutsem, Michel P. Ducreux, Sylvie Lorenzen, Stefano Cascinu
  • Chairs’ Conclusions
    Lesley J. Fallowfield, Elizabeth Smyth

Medscape Oncology Global
Improving Outcomes in Patients With High-Risk HR+/HER2- EBC: Keeping the Patient Central

Watch session

  • Welcome and introduction 
    Joyce O'Shaughnessy
  • How Would You Assess Risk of Recurrence in This Patient With HR+/HER2- EBC? Patient video will be included
    Wolfgang Janni
  • Treatment Considerations for Patients With High-Risk HR+/HER2- EBC: What do the Latest Data Show?
    Miguel Martin Jimenez
  • Keeping the Patient Central: Discussing Adherence and Persistence and the Role of the MDT Patient
    Sarah Donahue
  • Concluding Remarks
    Joyce O'Shaughnessy

Bristol Myers Squibb
The Treatment Paradigm Shift: Unlocking New Chapters with I-O in Thoracic Cancers

Watch session

  • Welcome and Introductions
    Virginie Westeel
  • Multidisciplinary Conversation: Putting I-O on the Table for Patients with Resectable NSCLC
    Jonathan Spicer
  • Considering the Options: Survivorship in Metastatic NSCLC and Potential Approaches for I-O–Experienced Patients
    Virginie Westeel
  • Making Progress for Patients: How I-O Has Changed Outcomes in Unresectable MPM
    Dean Fennell
  • Live Q&A and Closing Remarks
    Dean Fennell

11/09/2022

Ipsen
Disrupting the landscape: the Plus One in RCC and NSCLC

Watch session

  • Welcome & agenda
    Laurence Albiges
  • Triple, double and monotherapy: what is the sequence for best outcomes?
    Jens Bedke, Guillermo Antonio De Velasco Oria, Sumanta K. Pal
  • Expanding the armamentarium with IO-TKIs combinations – what can be learnt from RCC for the future of NSCLC?
    Laurence Albiges, Luis Paz-Ares, Sumanta K. Pal, Jens Bedke, Guillermo Antonio De Velasco Oria
  • Unmet needs in NSCLC: targeting second-line treatment with TKI-IO
    Luis Paz-Ares
  • Closing
    Laurence Albiges

GSK
Immune Checkpoint Inhibitors in Mismatch Repair Deficient Solid Tumors: Expert Interviews

Watch session

  • Clinical considerations for ICI treatment of dMMR endometrial cancer and other dMMR solid tumors
    Isabelle L. Ray-Coquard, Alexandra Leary, Andrea Cercek
  • Chair interview of Dr. Leary: Perspective on identifying patients with dMMR endometrial cancer for ICI treatment
    Alexandra Leary
  • Chair interview of Dr. Cercek: Perspective on single-agent PD-1 blockade in dMMR CRC/solid tumors
    Andrea Cercek
  • Panel discussion: Considerations for ICI treatment of dMMR endometrial cancer and CRC/solid tumors, expert perspectives
    Isabelle L. Ray-Coquard, Alexandra Leary, Andrea Cercek
  • Q&A
    Isabelle L. Ray-Coquard, Alexandra Leary, Andrea Cercek

F. Hoffmann-La Roche Ltd
Redefining Lung Cancer Together: Now and Next

Watch session

  • Welcome and Introduction
    Stephen Liu
  • Patient perspective: Where are we now?
    Stefania Vallone
  • Biomarkers in lung cancer: challenges and opportunities
    Frederique Penault-Llorca
  • Immunotherapy, targeted therapy and beyond: navigating options for metastatic disease
    Stephen Liu, Martin Reck
  • Treatment choice in early-stage lung cancer: new insights, new outlooks
    Martin Reck, Paul E. Van Schil
  • Panel discussion and Q&A
    Stephen Liu, Martin Reck, Frederique Penault-Llorca, Paul E. Van Schil, Stefania Vallone
  • Conclusion
    Stephen Liu, Stefania Vallone

Servier
Understanding the treatment strategy in metastatic pancreatic cancer to improve patient outcomes

Watch session

  • Introduction
    Thomas Seufferlein
  • Treatment planning strategy in mPAC
    Christoph Benedikt Westphalen    
  • Real-world data in mPAC
    Marc Peeters    
  • Insights from Japan in mPAC
    Masafumi Ikeda
  • Long-term survivors
    Teresa Macarulla Mercade
  • Panel discussion
    Teresa Macarulla Mercade, Thomas Seufferlein
  • Conclusion
    Thomas Seufferlein

Astellas
The maturing treatment landscape of mHSPC

Watch session

  • Welcome and introduction
    Stephane Oudard
  • Reap what you sow: Treatments for mHSPC in use today
    Ian D. Davis
  • Forget-me-nots: Unmet needs in mHSPC
    Shahrokh F. Shariat
  • The grass is greener: Deciding on the most appropriate initial treatment for patients with mHSPC
    Heather Payne
  • Q&A
    Stephane Oudard, Ian D. Davis, Heather Payne, Shahrokh F. Shariat
  • Closing remarks
    Stephane Oudard

12/09/2022

Medscape Oncology Global
Targets of Antibody-Drug Conjugates in NSCLC: Diagnostics, Emerging Therapies, and Future Prospects

Watch session

  • Personalizing Treatment in NSCLC: Recent Developments
    Enriqueta Felip
  • Novel ADC Targets in NSCLC: Rationale and Diagnostic Considerations
    Michael Thomas
  • Which Patients May Benefit From Emerging ADCs in NSCLC: Explaining the Clinical Trial Data
    Egbert F. Smit
  • Preparing the Clinics and Future Prospects
    Enriqueta Felip
  • Q&A Session
    Enriqueta Felip, Michael Thomas, Egbert F. Smit
  • Concluding Remarks
    Enriqueta Felip

F. Hoffmann-La Roche Ltd
What, why and how: Expert review and opinions on the potential of oral SERDs for our patients with HR+ BC

Watch session

  • Welcome and Introduction
    Nick Turner
  • What are oral SERDs and why do our patients need them?
    Komal Jhaveri
  • What have we seen from oral SERDs and what could they mean for our patients in future?
    Aditya Bardia
  • What’s next for oral SERDs and beyond for our patients with HR+ disease?
    Nick Turner
  • Q&A
    Nick Turner, Komal Jhaveri, Aditya Bardia
  • Close
    Nick Turner

Astellas Pharma Europe Ltd
Navigating the evolving landscape of locally advanced unresectable or metastatic G/GEJ adenocarcinoma

Watch session

  • Welcome and introductions
    Hanneke W. Van Laarhoven
  • The current landscape for locally advanced unresectable or metastatic G/GEJ adenocarcinoma
    Hanneke W. Van Laarhoven
  • Emerging treatments for locally advanced unresectable or metastatic G/GEJ adenocarcinoma
    Eric Van Cutsem
  • Working together in an evolving therapeutic landscape
    Hanneke W. Van Laarhoven, Mar Iglesias, Eric Van Cutsem
  • Q&A session
    Hanneke W. Van Laarhoven, Mar Iglesias, Eric Van Cutsem
  • Meeting summary and close
    Hanneke W. Van Laarhoven

Bristol Myers Squibb
The Evolving Treatment Landscape for Metastatic Melanoma: A Clinical Lens on Current Decision Making

Watch session

  • Welcome and introduction
    Paolo A. Ascierto
  • Emerging Data for the First-line Treatment of Metastatic Melanoma
    Nicolas Meyer
  • Considerations for Treatment Selection: A Case-Based Panel Discussion
    Hussein A. Tawbi
  • The Melanoma Continuum of Care: Remaining Challenges and Unmet Needs
    Paolo A. Ascierto
  • Summary and close
    Paolo A. Ascierto

Bristol Myers Squibb
Navigating the Integration of Immuno-Oncology Into the Perioperative Muscle-Invasive Urothelial Carcinoma Treatment Landscape

Watch session

  • Welcome and Introduction
    Andrea Necchi
  • The MIUC Treatment Landscape in 2022
    Morgan Roupret
  • Opportunities for I-O Use in the Perioperative Setting
    Margitta Retz
  • Optimising Patient Treatment: Perspectives on the Future Treatment Landscape
    Andrea Necchi
  • Interactive Multidisciplinary Team Meeting
    Andrea Necchi, Morgan Roupret, Margitta Retz
  • Q&A
    Andrea Necchi, Morgan Roupret, Margitta Retz     
  • Summary and Close
    Andrea Necchi

Seagen
Expert Opinion: Considerations for Managing HER2+ Breast Cancer and Brain Metastases

Watch session

  • Welcome and Introduction
    Diana I. Lüftner
  • The HER2+ breast cancer pathway
    Olivier Trédan
  • Managing brain metastases
    Pierfranco Conte
  • Brain metastases: challenging current perceptions
    Icro Meattini
  • Conclusions
    Diana I. Lüftner

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.